Mesa Laboratories INC /CO/ 10-Q quarterly reports

Mesa Laboratories, Inc. announced its first-quarter results, showing a 1.0% increase in revenue to $60.1 million and a 2.9 percentage point improvement in gross profit margin, though net income declined.

Mesa Laboratories, Inc. announced a significant turnaround in net income for the third quarter and nine months ended December 31, 2025, driven by revenue growth and improved operating efficiency, despite ongoing challenges in its Clinical Genomics division in China.

Mesa Laboratories reports 5% revenue growth in Q2 2025, but net income declined 27.8% due to China challenges and increased operating expenses, while strategic cost cuts are underway.

Mesa Laboratories reports a 2.4% revenue increase to $59.5 million in Q1 FY26, but operating income fell 45.1% due to higher expenses and lower gross margins, despite a boost from foreign currency gains.

Mesa Laboratories reports a 17.5% increase in revenue for Q3 2025, driven by the GKE acquisition and organic growth in several divisions, but discloses a material weakness in IT general controls.

Mesa Laboratories' second quarter results show revenue growth driven by the GKE acquisition, but also reflect challenges in the Clinical Genomics division and increased interest expenses.

Mesa Laboratories' first quarter of fiscal year 2025 saw a significant increase in revenue and operating income, boosted by the acquisition of GKE and organic growth in key divisions.

Mesa Laboratories' Q3 results show a slight revenue decrease and a significant increase in net income, influenced by acquisition costs and economic factors.